Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

BACKGROUND: Everolimus and sunitinib have been approved for the treatment advanced pancreatic neuroendocrine tumors, but have not been compared to each other in a randomized trial and have not demonstrated prolonged overall survival compared to placebo. This study aimed to indirectly compare overall...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Signorovitch, James, Swallow, Elyse, Kantor, Evan, Wang, Xufang, Klimovsky, Judith, Haas, Tomas, Devine, Beth, Metrakos, Peter
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4175512/
https://ncbi.nlm.nih.gov/pubmed/24314093
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2162-3619-2-32
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados